SARS‑COV‑2
CONVALESCENT PLASMA
Effectiveness varies according to host response. Antibody presentation from donated plasma shown to be more effective when administered early. For hospitalized severe patients, the administration of plasma did not significantly reduce recovery nor mortality rates. Causes attributed to dysregulated adaptive immune response and hyperinflammation from cytokines.
ORIGIN & ACCESS
ANTIBODY-BASED TREATMENT
SARS-COV-2
Treatment developed from Chinese Hamster Ovary (CHO) cells. Treatment effectiveness tested on human embryonic kidney (HEK) cells. A course of experimental treatment in addition to hospitalization costs, prescription drugs, testing, and quarantine would cost tens of thousands of dollars for high risk severe patients. Ventilators and intensive care unit (ICU) stays would make that amount skyrocket.
For plasma donation a person must have tested positive for COVID-19 and recovered. High enough antibody levels in their plasma must also be accompanied by the donor and patient having compatible blood types. The COVID antibodies they look for are IgG and IgM because IgM (detectable after 3 days) and IgG (8 days) represent that the body has mounted an antibody response against the virus